Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
METFOVIR: Metformin for HCC Prevention in HCV Cirrhosis
NCT02319200Phase 3Terminated
- Sponsor
- Assistance publique - Hôpitaux de Paris
- Start
- Jun 2015
- Primary completion
- Apr 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of liquid metformin (Aspargo Labs) in hepatocellular carcinoma (HCC), sponsored by Assistance publique - Hôpitaux de Paris. Primary endpoint: Rate of hepatocellular carcinoma occurrence, liver-related death, or liver transplantation at 6 months. Started Jun 2015; status: terminated.
02
Drugs
liquid metformin (Aspargo Labs)
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT02319200.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02319200.